Oncology Business Management

Investigators at Dana-Farber Cancer Institute in Boston, Massachusetts, developed a clinical outreach program combining diagnostic and patient navigation services.

CAR T-cell therapies have transformed the treatment landscape of multiple hematologic malignancies since they first rose to prominence, but they are associated with a high financial cost, both for the patient and the health care institution that provides them.

Here are 5 tips and tricks to help you shine when the spotlight is on you.

As artificial intelligence in cancer care continues to be better understood and refined, the number of potential clinical applications is rapidly expanding.

Prior authorization on cancer treatments is delaying patient care, affecting outcomes, and diverting providers from patient care according to results of a survey conducted by the Association for Clinical Oncology.

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.

Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.

Optimizing clinical pathways to address financial toxicities faced by patients with cancer requires a complex, multifaceted approach. However, even small in-practice changes may ease the financial burdens and improve outcomes.

Sequencing complexities with chemotherapy-based regimens in metastatic breast cancer pose unique challenges for valuebased decision-making in routine practice.

Maurie Markman, MD, elaborates on the need to take a closer look at the benchmarks used in clinical trial designs in oncology.

The publication of the objectively meaningful outcomes in high-impact peer-reviewed medical journals does not necessarily result in the observations being implemented into routine clinical care.

The National Cancer Act of 1971 introduced the concept of a “war on cancer,” which has since affected the language we use when discussing the disease.

Primary payer data reported by cancer registries are subject to measurement error and can result in biased estimates of insurance-related policy effects.

The expansion of technology includes machine learning, which is quickly emerging as a dynamic aid for clinicians in every aspect of cancer care, from diagnosis to treatment decisions.

Digital health solutions have the potential to improve outcomes via remote symptom monitoring, increase patient/physician communication, and improve patient education.

From evaluating clinical outcomes to determining payment for services, measurements are important in health care.

For decades in cancer care, the compiling of patient-reported outcomes was limited to simple standardized questionnaires completed with pen and paper.

Developing a system with a patient-centric focus, investigators at Yale Cancer Center and Moffitt Cancer Center initiated pilot programs to offer patients better access to care following a diagnosis of cancer.

Data-driven health economics and outcomes research offers clinicians effective methods for improving quality of life and outcomes for patients and optimizing economic benefits for the practice.

Maurie Markman, MD, discusses the need for oncologists to improve communication with the public and patients.

As cancer care continues to shift away from a fee-for-service model to a value-based care model, clinicians and institutions will need to be adaptable and innovative to build effective community oncology practices of the future.

Pragmatic clinical trials “inform a clinical or policy decision by providing evidence for adoption of the intervention into real-world clinical practice.”

As technology and cancer care continue to become intertwined at every level, there is an imperative need to effectively process and use vast amounts of data to provide the highest level of care for patients.

Maurie Markman, MD, discusses the obstacles presented to cancer efforts as a result of challenges to scientific authority during the COVID-19 pandemic.

New FDA guidelines reflect improvements in medical science over the past 6 years and are designed to facilitate continued advancement in cancer prevention, detection, research, and patient care.

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

Fill rates of data elements on electronic health records are a major contributing factor limiting the uptake of automated services.

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share their experiences as a fellowship director and an oncology fellow, respectively.

Maurie Markman, MD, discusses the debate between surrogate end points of overall survival and progression-free survival in clinical trials within oncology.

Patient education in oncology can often be daunting and complicated for clinicians and patients.